Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening ...
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and ...
15d
Why Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA Plans
Structure Therapeutics recently reported encouraging Phase 2 ACCESS II trial results for its oral GLP-1 receptor agonist aleniglipron, showing up to 16.3% weight reduction in adults with obesity and ...
New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.In return for ...
A study by Professor Carlos Matute of the EHU reinforces a paradigm shift in neuroscience: Myelin goes from being a ...
Only two months after snagging $150 million from investors to take its first G-protein-coupled receptor (GPCR) drug into the clinic, Septerna has added another $47.5 million to the pile courtesy of a ...
It is a characteristic of cell membrane receptors, which is shared by GPCRs along with G-protein associates. The process of receptor oligomerization is assisted by the cell thermodynamics as well as ...
G protein-coupled receptors (GPCRs) remain one of the most pharmacologically successful drug targets, with 35% of all commercial drugs and 19% of newly approved drugs targeting this protein ...
View Structure Therapeutics, Inc. Sponsored ADR GPCR stock quote prices, financial information, real-time forecasts, and company news from CNN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results